SPYGLASS PHARMA INC SHS (SGP)
Health Care · ophthalmology / medical technology · NASDAQ
Spyglass Pharma is developing a novel, integrated drug-delivery system to improve the administration of therapeutic medication during cataract surgery.
What SPYGLASS PHARMA INC SHS does
Spyglass Pharma is a clinical-stage medical technology and biopharmaceutical company developing novel ocular drug delivery systems. Its lead product candidate is the Bimatoprost Drug Pad-IOL System, an integrated system designed to deliver sustained-release medication during cataract surgery.
Themes: ophthalmology, cataract surgery, sustained-release drug delivery, drug-device combination products
Fundamentals
- Price$26.16 as of 2026-10-20 close
- Market cap$875M as of 2026-07-29 (share count; price 2026-10-20)
- P/En/a negative earnings
- ROICn/a No figure: its pre-tax income was zero or negative, so there is no tax rate to apply.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Beta1.39 as of 2026-09-02
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How SGP compares in its sector
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$22M | -$20M | -$0.59 | -$15M† | $2M† |
| Q1 FY2026 2026-03-31 | -$15M | -$14M | -$0.69 | -$14M | $676000 |
| Q2 FY2025 2025-06-30 | -$9M | -$9M | -$3.81 | -$6M† | $52000† |
| Q1 FY2025 2025-03-31 | -$7M | -$9M | -$3.96 | -$8M | $164000 |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$223M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How SPYGLASS PHARMA INC SHS looks technically
SPYGLASS PHARMA INC SHS (SGP): a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 5 trading days ago.
Trend
8
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $26.50 | $26.50 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 27. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 25, with buyers in control | 25.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 53, neither overbought (above 70) nor oversold (below 30) | 53.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($22.80 to $27.11) — its "stochastic" reading is 78 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 78.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
7
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
|---|---|---|
| Since a 55-day breakout | it made a new 55-day high about 24 trading days ago | 24 sessions |
| All-time high | its highest closing price on record is $32.44 (set on 2026-02-06) | $32.44 |
| Given back of the 52-week move | not available for this company yet | n/a |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $17.06 (set on 2026-06-17) | $17.06 |
| Above the all-time low | it is 53.3% above its all-time low | +53.3% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 34th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.52 between its high and its low — about 5.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.52 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $22.92 and $27.83 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $22.92 – $25.37 – $27.83 |
| Typical daily range (% of price) | its price moves about 5.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.80× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-20 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Gap filled | a 3.3% gap down opened on 2026-09-01 has been "filled" 34 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 34 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +9% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 11.0 percentage points (the stock lost 10.0% while the market gained 1.0%) | -11.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 27.0 percentage points (the stock gained 30.7% while the market gained 3.6%) | +27.0% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 1.8 percentage points (the stock gained 6.7% while the market gained 8.5%) | -1.8% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 2 of the 7 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, a strong uptrend, with buyers in control — these describe past price behaviour, not a forecast | 2 of 7 |
|---|---|---|
| Bearish technical signals | 1 of the 7 technical signals we can compute for it is currently in a bearish state: lagging the market over 6 months — these describe past price behaviour, not a forecast | 1 of 7 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 10.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% above the average price paid since 2026-02-06, so the typical buyer over that stretch is showing a gain. That average is $24.55 — a volume-weighted average of daily closes over 167 sessions, not a true tick-by-tick VWAP. | +6.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $27.05 — a volume-weighted average of daily closes over 53 sessions, not a true tick-by-tick VWAP. | -3.3% |
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $27.00.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $25.71 and $27.00 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $24.39.
This reading has stood for 11 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 50-day moving average · MACD just crossed bullish (12/26/9) · in a strong, established uptrend (ADX) · Under water since its last earnings report (below the anchored VWAP) · Trading inside the Ichimoku cloud · Elliott wave 4 pullbacks | Learn: adx · rsi · macd · breakout
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$44.00 range $37.00 – $62.00; median $42.00
Analyst estimates, as of 2026-10-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SGP
- Consensus EPS estimate-$0.6225 next reporting period, as of 2026-10-19
- Estimate change, 30 days-$0.00127 from -$0.6212, on 2026-09-14, 35-day window
- Readings revised upward0% of 10 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on clinical trials to demonstrate safety and efficacy of product candidates.","Need for additional financing and capital to support future operations and commercialization efforts.","Risks related to regulatory approval processes and third-party manufacturing dependencies."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
Cluster buying: 11 different insiders reported open-market purchases (SEC code P) of SGP within a 30-day window between 2026-02-09 and 2026-02-09. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-02-09. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SGP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding SGP as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 830,770
- Reported value $18,492,940
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 2 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about SGP's institutional holders → See what each manager we track holds →
Short interest (FINRA)
SGP had 1,253,724 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
SGP had 3.75% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 7.11 days to cover at the same settlement.
- Reported short interest (shares) 1,253,724
- Short interest (% of shares outstanding) 3.75%
- Prior settlement (shares) 1,229,711
- Reported change 1.95%
- Days to cover (reported) 7.11
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
SPYGLASS PHARMA INC SHS is found in…
Frequently asked questions
What does SPYGLASS PHARMA INC SHS (SGP) do?
Spyglass Pharma is a clinical-stage medical technology and biopharmaceutical company developing novel ocular drug delivery systems. Its lead product candidate is the Bimatoprost Drug Pad-IOL System, an integrated system designed to deliver sustained-release medication during cataract surgery.
What sector is SPYGLASS PHARMA INC SHS (SGP) in?
SPYGLASS PHARMA INC SHS (SGP) is classified in the Health Care sector. Its industry is ophthalmology / medical technology. It trades on NASDAQ.
Is SPYGLASS PHARMA INC SHS (SGP) overbought or oversold right now?
SPYGLASS PHARMA INC SHS (SGP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 53, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SGP come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.